TRASTYVERE

OFFICIAL TITLE: CLINICAL BENEFIT OF THE TREATMENT WITH TRASTUZUMAB IN COMBINATION WITH LAPATINIB IN METASTATIC BREAST CANCER HER2 POSITIVE PATIENTS WHO HAS BEEN PREVIOUSLY TREATED WITH TRASTUZUMAB AND/OR LAPATINIB.

SABCS 2014 - DOWNLOAD THE POSTER

ECCO/ASCO 2014 - DOWNLOAD THE POSTER

PROJECT DETAILS

OBSERVATIONAL, RETROSPECTIVE AND MULTICENTER STUDY TO EVALUATE THE CLINICAL BENEFIT OF TRASTUZUMAB IN COMBINATION WITH LAPATINIB IN METASTATIC BREAST CANCER HER2 POSITIVE PATIENTS WHO HAS BEEN PREVIOUSLY TREATED WITH TRASTUZUMAB AND/OR LAPATINIB.

 

A RETROSPECTIVE, OBSERVATIONAL, NOT EPA, MULTICENTER STUDY TO EVALUATE THE CLINICAL BENEFIT OF TRASTUZUMAB IN COMBINATION WITH LAPATINIB IN METASTATIC BREAST CANCER HER2 POSITIVE PATIENTS WHO HAS BEEN PREVIOUSLY TREATED WITH TRASTUZUMAB AND/OR LAPATINIB BETWEEN JANUARY 2005 AND DECEMBER 2011.

TRASTYVERE AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

BREAST
(Her2-)

RETROSPECTIVE

111

11

Spain

Accrual
Finalized

N

SITES

COUNTRY

STATUS

TRASTYVERE SITES

SPAIN

(11)